Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
$7.93
-3.5%
$9.64
$4.88
$19.58
$172.05MN/A131,488 shs44,223 shs
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
$1.14
+5.6%
$1.23
$0.80
$3.20
$46.84M-1.1318,270 shs8,524 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.26
-3.2%
$15.24
$5.22
$27.38
$153.88M0.75128,210 shs77,510 shs
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
$3.15
-4.5%
$3.43
$2.76
$7.51
$148.47M0.2615,171 shs5,291 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
0.00%+13.29%+2.45%+792,999,900.00%+792,999,900.00%
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
0.00%+12.87%-16.18%-24.01%-57.83%
LifeVantage Co. stock logo
LFVN
LifeVantage
0.00%-8.71%-14.98%-43.00%+98.22%
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
0.00%-5.69%-13.20%-8.16%-45.12%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
2.0436 of 5 stars
3.53.00.00.01.91.70.0
LifeVantage Co. stock logo
LFVN
LifeVantage
3.8899 of 5 stars
3.51.01.72.72.42.50.6
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
1.9426 of 5 stars
3.33.00.00.02.70.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
3.00
Buy$31.50297.23% Upside
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
3.00
Buy$8.00601.75% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50148.78% Upside
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.00153.97% Upside

Current Analyst Ratings Breakdown

Latest ANEB, LFVN, AARD, and NBTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2025
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $8.00
4/1/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.00
4/1/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.00
3/27/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$22.00 ➝ $26.00
3/10/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$29.00
3/10/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$22.00
3/10/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$21.00
3/10/2025
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$50.00
2/17/2025
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/AN/A
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/A$0.15 per shareN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$212.15M0.73$0.64 per share19.03$2.38 per share5.15
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
-$11.61M-12.79N/AN/A($0.04) per share-78.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$8.20M-$0.28N/AN/AN/A-119.54%-108.08%5/13/2025 (Estimated)
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.5621.89N/A3.46%34.29%15.04%5/6/2025 (Estimated)
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
-$42.97MN/A0.00N/AN/AN/AN/AN/A5/20/2025 (Estimated)

Latest ANEB, LFVN, AARD, and NBTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q3 2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
-$0.05N/AN/AN/AN/AN/A
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.1633N/AN/AN/A$60.99 millionN/A
2/14/2025Q2 2025
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A-$0.09N/A-$0.09N/AN/A
2/5/2025Q2 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.14$0.22+$0.08$0.19$67.41 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/A
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.161.31%N/A28.57%N/A
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A

Latest ANEB, LFVN, AARD, and NBTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/3/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.040.7%3/3/20253/3/20253/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/A
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
N/A
17.51
17.51
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
N/A
1.42
N/A

Institutional Ownership

CompanyInstitutional Ownership
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
28.40%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
38.81%

Insider Ownership

CompanyInsider Ownership
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
80.60%
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
3.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
1821.70 millionN/AN/A
Anebulo Pharmaceuticals, Inc. stock logo
ANEB
Anebulo Pharmaceuticals
441.09 million5.79 millionNot Optionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.55 million9.96 millionOptionable
Nanobiotix S.A. stock logo
NBTX
Nanobiotix
10047.13 million45.51 millionNot Optionable

Recent News About These Companies

Nanobiotix price target lowered to $8 from $12 at Guggenheim
Nanobiotix (NBTX) Gets a Hold from UBS
Nanobiotix files $200M mixed securities shelf
Nanobiotix files to sell 5.62M ordinary shares for holders
Nanobiotix downgraded to Neutral from Buy at UBS
UBS downgrades Nanobiotix (NBTX) to a Hold
7 Best Nanotech Penny Stocks to Invest In

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aardvark Therapeutics stock logo

Aardvark Therapeutics NASDAQ:AARD

$7.93 -0.29 (-3.53%)
As of 04/25/2025 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Anebulo Pharmaceuticals stock logo

Anebulo Pharmaceuticals NASDAQ:ANEB

$1.14 +0.06 (+5.56%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$1.15 +0.01 (+0.79%)
As of 04/25/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.26 -0.41 (-3.24%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$11.94 -0.32 (-2.61%)
As of 04/25/2025 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$3.18 -0.12 (-3.61%)
As of 04/25/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.